Miconazole Nitrate + Polymyxin B Sulfate + Prednisolone Acetate

Verify with FDA CVM →

214 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
214
Total Reports
3
Deaths Reported
140.0%
Death Rate

Active Ingredients

Miconazole NitratePolymyxin B SulfatePrednisolone Acetate

Administration Routes

Auricular (Otic)OralTopicalUnknownOphthalmicOtherIntraocular

Species Affected

Dog 207
Cat 5
Human 1
Rat 1

Most Affected Breeds

Retriever - Labrador 20
Crossbred Canine/dog 17
Dog (unknown) 15
Shih Tzu 10
Terrier - Yorkshire 9
Terrier - Boston 8
Chihuahua 8
Maltese 6
Pit Bull 6
Boxer (German Boxer) 6

Most Reported Reactions

Deafness 66
Loss of hearing 42
Lack of efficacy - NOS 21
Behavioural disorder NOS 19
Emesis 16
Hearing decreased 15
Impaired hearing 13
Partial deafness 12
Lethargy (see also Central nervous system depression in 'Neurological') 12
Diarrhoea 11
Ear infection NOS 8
Head shake - ear disorder 7

Outcome Breakdown

Recovered/Normal
74 (34.7%)
Outcome Unknown
69 (32.4%)
Recovered with Sequela
59 (27.7%)
Ongoing
8 (3.8%)
Euthanized
2 (0.9%)
Died
1 (0.5%)

Data Summary

Metric Value
Total adverse event reports 214
Reports involving death 3
Case-fatality rate (reported events) 140.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Miconazole Nitrate + Polymyxin B Sulfate + Prednisolone Acetate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 214 adverse event reports referencing Miconazole Nitrate + Polymyxin B Sulfate + Prednisolone Acetate, including 3 reports in which the animal died — a 140.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Miconazole Nitrate, Polymyxin B Sulfate, Prednisolone Acetate. Reported administration routes include Auricular (Otic), Oral, Topical, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Miconazole Nitrate + Polymyxin B Sulfate + Prednisolone Acetate reports are Dog (207 reports), Cat (5 reports), Human (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (20), Crossbred Canine/dog (17), Dog (unknown) (15) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Miconazole Nitrate + Polymyxin B Sulfate + Prednisolone Acetate are Deafness (66), Loss of hearing (42), Lack of efficacy - NOS (21), Behavioural disorder NOS (19). Of the 213 reports with a coded outcome, Recovered/Normal is the leading category at 34.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Miconazole Nitrate + Polymyxin B Sulfate + Prednisolone Acetate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial